Max represents private and public companies in transactional and general corporate matters, including entity formation, corporate governance, mergers & acquisitions, private financings, public offerings, and SEC reporting and compliance.
Structure Therapeutics Announces Upsized $547.4 Million Public Offering
June 7, 2024
Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering.
